The combined treatment with multiple deubiquitinase inhibitors, including betulinic acid or WP1130 and enzalutamide, reduced AR protein stability and mRNA expression in PC cells, making it an attractive strategy for CRPC treatment [101]. This evidence concerns the gene AR and pachyonychia congenita.